This commentary discusses the growing debate on the use of radioactive iodine treatment (RAIT) in pediatric papillary thyroid carcinoma (PTC). Based on recent adult trials and emerging pediatric data, it hypothesizes that some children may currently be overtreated and outlines the European studies needed to guide future management strategies.

Ped-DTC registry: The development of a pediatric differentiated thyroid carcinoma registry within the EuRRECa project aims to systematically collect high-quality clinical data across Europe. The article describes the registry’s design, data collection methods, and governance structure, as well as how it enables collaboration between centres. It highlights the types of clinical, diagnostic, and outcome data captured, and explains how the registry will support research and improve care for children with differentiated thyroid carcinoma.

The 2022 European Thyroid Association Guidelines provide comprehensive, evidence-based recommendations for the diagnosis, treatment, and follow-up of pediatric thyroid carcinoma. These guidelines support harmonised, high-quality care across Europe and serve as an important reference for clinicians and researchers.

This recent European collaboration explores personalised approaches to the management of pediatric differentiated thyroid carcinoma (ped-DTC). The article discusses the unique characteristics of ped-DTC, current treatment challenges, and the potential risks of overtreatment. It highlights the launch of the European ped-DTC registry within the EuRRECa project. Readers can also learn about the first linked study, STRATIFY, aimed at developing prognostic models to guide surgical and postoperative management.